Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine

Nuclear Medicine and Biology

Volumn 37, Issue 5, 2010, Pages 539-546

  Ahlgren, Sara ^a   Andersson, Kristofer ^b   Tolmachev, Vladimir ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affibody molecules; Freeze drying lyophilization; HER2; Imaging; Kit formulation; Technetium

Indexed keywords

BUFFER; EDETIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; GLUCOHEPTONIC ACID; PERTECHNETIC ACID TC 99M; PHOSPHATE; RECOMBINANT ANTIBODY; SODIUM CHLORIDE; TECHNETIUM 99M; TIN CHLORIDE; UNCLASSIFIED DRUG; ALPHA GLUCOHEPTONIC ACID; ALPHA-GLUCOHEPTONIC ACID; ANTIBODY; CYSTEINE; RECOMBINANT PROTEIN; STANNOUS CHLORIDE; SUGAR ACID; TECHNETIUM COMPLEX; TIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; CHEMICAL COMPOSITION; COLLOID; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; FREEZE DRYING; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SERUM; SHELF LIFE; ANIMAL; CHEMISTRY; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; PROTEIN ENGINEERING; REPRODUCIBILITY; TIME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES; CELL LINE, TUMOR; CYSTEINE; EDETIC ACID; FEMALE; FREEZE DRYING; HUMANS; ISOTOPE LABELING; MICE; ORGANOTECHNETIUM COMPOUNDS; PROTEIN ENGINEERING; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; SODIUM PERTECHNETATE TC 99M; SUGAR ACIDS; TIME FACTORS; TIN COMPOUNDS;

EID: 77953872478     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.02.009     Document Type: Article

References (19)

1. Bast R.C., Ravdin P., Hayes D.F., Bates S., Fritsche H., Jessup J.M., et al. American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19:1865-1878.
2. Molina R., Barak V., van Dalen A., Duffy M.J., Einarsson R., Gio M., et al. Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol 2005, 26:281-293.
3. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354.
4. Baselga J., Perez E.A., Pienkowski T., Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006, 11(suppl 1):4-12.
5. Scaltriti M., Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006, 12:5268-5272.
6. Perez E.A., Suman V.J., Davidson N.E., Martino S., Kaufman P.A., Lingle W.L., et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006, 24:3032-3038.
7. Rasbridge S.A., Gillett C.E., Seymour A.M., Patel K., Richards M.A., Rubens R.D., et al. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 1994, 70:335-341.
8. Kenanova V., Wu A.M. Tailoring antibodies for radionuclide delivery. Expert Opin Drug Deliv 2006, 3:53-70.
9. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des 2008, 14:2999-3019.
10. Tolmachev V., Orlova A. Update on Affibody molecules for in vivo imaging of targets for cancer therapy. Minerva Biotecnol 2009, 21:21-30.
11. Orlova A., Magnusson M., Eriksson T.L., Nilsson M., Larsson B., Höidén-Guthenberg I., et al. Tumor imaging using a picomolar affinity HER2 binding Affibody molecule. Cancer Res 2006, 66:4339-4348.
12. Ahlgren S., Orlova A., Rosik D., Sandström M., Sjöberg A., Baastrup B., et al. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant Affibody molecules. Bioconjug Chem 2008, 19:235-243.
13. HER2:2395-Cys Affibody molecule for targeting of HER2-expressing tumors. Mol Imaging Biol 2010, 12:54-62.
14. 99mTc-labeled recombinant Affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. J Nucl Med 2009, 50:781-789.
15. 99mTc to tumor-targeting Affibody molecules. Bioconjug Chem 2007, 18:549-558.
16. Kowalsky R.J., Dalton D.R. Technical problems associated with the production of technetium Tc 99m tin(II) pyrophosphate kits. Am J Hosp Pharm 1981, 38:1722-1726.
17. 99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis. J Pharm Sci 2004, 93:2497-2506.
18. Orlova A., Tolmachev V., Pehrson R., Lindborg M., Tran T., Sandström M., et al. Synthetic Affibody molecules: A novel class of affinity ligands for molecular imaging of HER2 expressing malignant tumors. Cancer Res 2007, 67:2178-2189.
19. Behr T.M., Goldenberg D.M., Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998, 25:201-212.